FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285095509> ?p ?o ?g. }

• W4285095509 endingPage "1449" @default.
• W4285095509 startingPage "1449" @default.
• W4285095509 abstract "Naringenin (NRG) is a flavonoid and has been reported as an anti-osteoporotic agent. However, poor bioavailability may limit the anti-osteoporotic potential of the drug. The purpose of the study was to compare the anti-osteoporotic activity of naringenin nanosuspension (NRG-NS) with the NRG and standard therapeutic drug, raloxifene hydrochloride (RLX). Here, NRG-NS showed anti-osteoporotic activity in MG-63 cells by upregulating the osteocalcin levels. The in vivo anti-osteoporotic activity of NRG-NS was further investigated in an osteoporotic rat model to mimic the post-menopausal condition. The animals were randomized and separated into six groups. The animals were treated with RLX (p.o., 5.4 mg/kg), NRG (p.o., 20 mg/kg), NRG-NS (p.o., 20 mg/kg), and blank-NS for 60 days after completion of a 30-day post-surgery period and compared with control and ovariectomized (OVX) groups. After the treatment, body and uterine weights, biochemical estimation in serum (calcium, phosphorus, acid phosphatase, alkaline phosphatase, osteocalcin), bone parameters (length, diameter, dry weight, density, ash weight, bone mineral content) and bone microarchitecture by histopathology were determined. The results showed the protective effects of NRG-NS on osteoblast-like MG-63 cells. The biochemical estimations confirmed the normalization of parameters viz., alkaline phosphatase, calcium concentrations, and bone density with a decrease in levels of acid phosphatase and inorganic phosphorus with NRG-NS as compared to plain NRG. The results indicated that the oral administration of NRG-NS could be a potential therapeutic formulation for the treatment of osteoporosis." @default.
• W4285095509 created "2022-07-14" @default.
• W4285095509 creator A5002884335 @default.
• W4285095509 creator A5042890653 @default.
• W4285095509 creator A5049447867 @default.
• W4285095509 creator A5050715036 @default.
• W4285095509 creator A5060203055 @default.
• W4285095509 creator A5081580438 @default.
• W4285095509 date "2022-07-11" @default.
• W4285095509 modified "2023-10-06" @default.
• W4285095509 title "Therapeutic Potential of Naringenin Nanosuspension: In Vitro and In Vivo Anti-Osteoporotic Studies" @default.
• W4285095509 cites W1264540065 @default.
• W4285095509 cites W1517095527 @default.
• W4285095509 cites W1524387806 @default.
• W4285095509 cites W1576568858 @default.
• W4285095509 cites W1607811082 @default.
• W4285095509 cites W1919397066 @default.
• W4285095509 cites W1931078429 @default.
• W4285095509 cites W1975116096 @default.
• W4285095509 cites W1981930609 @default.
• W4285095509 cites W1987354408 @default.
• W4285095509 cites W2017120735 @default.
• W4285095509 cites W2019864056 @default.
• W4285095509 cites W2020680151 @default.
• W4285095509 cites W2027016449 @default.
• W4285095509 cites W2032752377 @default.
• W4285095509 cites W2036674463 @default.
• W4285095509 cites W2040149069 @default.
• W4285095509 cites W2055834324 @default.
• W4285095509 cites W2056691825 @default.
• W4285095509 cites W2057645731 @default.
• W4285095509 cites W2060747237 @default.
• W4285095509 cites W2084209221 @default.
• W4285095509 cites W2096234941 @default.
• W4285095509 cites W2098505104 @default.
• W4285095509 cites W2103037903 @default.
• W4285095509 cites W2110396808 @default.
• W4285095509 cites W2121292799 @default.
• W4285095509 cites W2123346255 @default.
• W4285095509 cites W2130169906 @default.
• W4285095509 cites W2135170371 @default.
• W4285095509 cites W2137058982 @default.
• W4285095509 cites W2142478701 @default.
• W4285095509 cites W2142586148 @default.
• W4285095509 cites W2144783796 @default.
• W4285095509 cites W2156075512 @default.
• W4285095509 cites W2171394262 @default.
• W4285095509 cites W2335640937 @default.
• W4285095509 cites W2588908242 @default.
• W4285095509 cites W2592857905 @default.
• W4285095509 cites W2620427326 @default.
• W4285095509 cites W2647028854 @default.
• W4285095509 cites W2776159526 @default.
• W4285095509 cites W2910047871 @default.
• W4285095509 cites W2911804254 @default.
• W4285095509 cites W3025534491 @default.
• W4285095509 cites W3033787366 @default.
• W4285095509 cites W3097073698 @default.
• W4285095509 cites W3150735255 @default.
• W4285095509 cites W3165122850 @default.
• W4285095509 cites W3202787125 @default.
• W4285095509 cites W3211878495 @default.
• W4285095509 cites W4224210246 @default.
• W4285095509 cites W4224218448 @default.
• W4285095509 cites W4243483386 @default.
• W4285095509 cites W4253407136 @default.
• W4285095509 doi "https://doi.org/10.3390/pharmaceutics14071449" @default.
• W4285095509 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35890343" @default.
• W4285095509 hasPublicationYear "2022" @default.
• W4285095509 type Work @default.
• W4285095509 citedByCount "15" @default.
• W4285095509 countsByYear W42850955092022 @default.
• W4285095509 countsByYear W42850955092023 @default.
• W4285095509 crossrefType "journal-article" @default.
• W4285095509 hasAuthorship W4285095509A5002884335 @default.
• W4285095509 hasAuthorship W4285095509A5042890653 @default.
• W4285095509 hasAuthorship W4285095509A5049447867 @default.
• W4285095509 hasAuthorship W4285095509A5050715036 @default.
• W4285095509 hasAuthorship W4285095509A5060203055 @default.
• W4285095509 hasAuthorship W4285095509A5081580438 @default.
• W4285095509 hasBestOaLocation W42850955091 @default.
• W4285095509 hasConcept C126322002 @default.
• W4285095509 hasConcept C131075544 @default.
• W4285095509 hasConcept C134018914 @default.
• W4285095509 hasConcept C150903083 @default.
• W4285095509 hasConcept C160160445 @default.
• W4285095509 hasConcept C178790620 @default.
• W4285095509 hasConcept C181199279 @default.
• W4285095509 hasConcept C181389837 @default.
• W4285095509 hasConcept C185592680 @default.
• W4285095509 hasConcept C207001950 @default.
• W4285095509 hasConcept C2776541429 @default.
• W4285095509 hasConcept C2776848411 @default.
• W4285095509 hasConcept C2776886416 @default.
• W4285095509 hasConcept C2778004101 @default.
• W4285095509 hasConcept C2779054382 @default.
• W4285095509 hasConcept C519063684 @default.
• W4285095509 hasConcept C55493867 @default.

• next